Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Complete Response Letters In Lieu Of Inspections: What To Expect During COVID-19

Executive Summary

If agency has concerns about facilities it cannot inspect, it will generally issue complete responses, Q&A guidance says.

You may also be interested in...



Novartis Counts On Adherence, Access And Affordability To Ensure Inclisiran’s US Success

The company has said coverage under medical benefit could mean $0 copays for many patients, potentially overcoming a hurdle to uptake in the biologic cholesterol market.

US FDA Cautions Against Blaming CRLs On Inspection Delays

Agency revises pandemic inspection guidance to explain CRL ‘non-deficiency’ inspection comments and update industry on remote interactive evaluations and post-COVID-19 inspection priorities.

US FDA Explains Why Remote Interactive Evaluations Guidance Took So Long

Time taken for interagency alignment, lessons learned from foreign counterparts will increase use of remote video tours, say FDA officials..

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS142764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel